Escape from immune surveillance does not result in tolerance to tumor-associated antigens

Journal of Immunotherapy

Volumn 27, Issue 5, 2004, Pages 329-338

  Melchionda, Fraia ^a,b   McKirdy, Melissa K ^a   Medeiros, Filomena ^a,c   Fry, Terry J ^a   Mackall, Crystal L ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^d MSC 1928 ^*  (United States)

Author keywords

Antigens peptides epitopes; Rodent; T lymphocytes; Tolerance suppression anergy; Tumor immunity

Indexed keywords

HY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; RECOMBINANT INTERLEUKIN 7; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CLONAL ANERGY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR GROWTH;

EID: 4344672799     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200409000-00001     Document Type: Article

References (60)

1. Burnet M. Immunological surveillance in neoplasia. Transplant Rev. 1971;7:3-25.
2. Shankaran V, Ikeda H, Bruce AT, et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-1111.
3. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by gamma/delta t cells. Science. 2001;294:605-609.
4. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13:459-463.
5. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998;95:7556-7561.
6. Street SE, Trapani JA, MacGregor D, et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med. 2002; 196:129-134.
7. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA. 1998;95:1178-1183.
8. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA. 1999;96:2233-2238.
9. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725-729.
10. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.
11. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170:85-100.
12. Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183:1185-1192.
13. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
14. Forsthuber T, Yip HC, Lehmann PV. Induction of Th1 and Th2 immunity in neonatal mice. Science. 1996;271:1728-1730.
15. Whiteside TL. Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol Invest. 2000;29:149-162.
16. Yee C, Greenberg P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer. 2002;2:409-419.
17. Clay TM, Hobeika AC, Mosca PJ, et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res. 2001;7:1127-1135.
18. Fry TJ, Christensen BL, Komschlies KL, et al. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood. 2001;97:1525-1533.
19. Halak BK, Maguire HC Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 1999;59:911-917.
20. Fry TJ, Moniuszko M, Creekmore S, et al. Il-7 therapy dramatically alters peripheral T-cell homeostasis in normal and HIV-infected nonhuman primates. Blood. 2003;101:2294-2299.
21. Billingham R, Medawar RB. The technique of free skin grafting in mammals. J Exp Biol. 1951;28:385.
22. Millrain M, Chandler P, Dazzi F, et al. Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J Immunol. 2001;167:3756-3764.
23. Maile R, Wang B, Schooler W, et al. Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J Immunol. 2001;167:3708-3714.
24. King TR, Christianson GJ, Mitchell MJ, et al. Deletion mapping by immunoselection against the H-Y histocompatibility antigen further resolves the SXRA region of the mouse Y chromosome and reveals complexity of the HYA locus. Genomics. 1994;24:159-168.
25. Scott DM, Ehrmann IE, Ellis PS, et al. Identification of a mouse male-specific transplantation antigen, H-Y. Nature. 1995;376:695-698.
26. Scott D, Addey C, Ellis P, et al. Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens. Immunity. 2000;12:711-720.
27. Karulin AY, Hesse MD, Tary-Lehmann M, et al. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J Immunol. 2000;164:1862-1872.
28. Rosenberg AS, Mizuochi T, Sharrow SO, et al. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J Exp Med. 1987;165:1296-1315.
29. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998;95:7556-7561.
30. Czerkinsky CC, Nilsson LA, Nygren H, et al. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 1983;65:109-121.
31. Czerkinsky C, Andersson G, Ekre HP, et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon- secreting cells. J Immunol Methods. 1988;110:29-36.
32. Simpson E, Scott D, Chandler P. The male-specific histocompatibility antigen, H-Y: a history of transplantation, immune response genes, sex determination and expression cloning. Annu Rev Immunol. 1997;15: 39-61.
33. Schluns KS, Kieper WC, Jameson SC, et al. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol. 2000;1:426-432.
34. Tan JT, Ernst B, Kieper WC, et al. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med. 2002;195: 1523-1532.
35. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445-480.
36. Pardoll D. T cells and tumours. Nature. 2001;411:1010-1012.
37. Rohrer JW, Coggin JH Jr. Cd8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol. 1995;155:5719-5727.
38. Scheibenbogen C, Romero P, Rivoltini L, et al. Quantitation of antigen-reactive T cells in peripheral blood by IFN-gamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods. 2000;244:81-89.
39. Schmittel A, Keilholz U, Thiel E, et al. Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother. 2000;23:289-295.
40. Helms T, Boehm BO, Asaad RJ, et al. Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J Immunol. 2000;164:3723-3732.
41. Ekerfelt C, Ernerudh J, Jenmalm MC. Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR. J Immunol Methods. 2002;260:55-67.
42. Schlick E, Hewetson P, Ruffmann R. Adjuvant chemoimmunotherapy of cancer: influence of tumor burden and role of functional immune effector cells in mice. Cancer Res. 1986;46:3378-3383.
43. Lannin DR, Yu S, McKhann CF. Thymus-dependent response: too little and too late for immunosurveillance. Transplantation. 1982;33:99-100.
44. Fefer A, Einstein AB Jr, Cheever MA, et al. Models for syngeneic adoptive chemoimmunotherapy of murine leukemias. Ann NY Acad Sci. 1976; 276:573-583.
45. Hanson HL, Donermeyer DL, Ikeda H, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 2000;13: 265-276.
46. Nguyen LT, Elford AR, Murakami K, et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med. 2002;195:423-435.
47. Speiser DE, Miranda R, Zakarian A, et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med. 1997;186:645-653.
48. Shrikant P, Mescher MF. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol. 1999;162:2858-2866.
49. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity. 1999; 11:183-190.
50. Ernst B, Lee DS, Chang JM, et al. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity. 1999;11:173-181.
51. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110: 185-192.
52. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
53. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983-2990.
54. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. 2001;22:564-571.
55. Bolotin E, Annett G, Parkman R, et al. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 1999;23:783-788.
56. Tan JT, Dudl E, LeRoy E, et al. Il-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA. 2001;10:10.
57. Mackall CL, Bare CV, Titus JA, et al. Thymic-independent T cell regeneration occurs via antigen driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol. 1996;156:4609-4616.
58. Mackall CL, Fry TJ, Bare C, et al. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood. 2001;97:1491-1497.
59. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.
60. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276.